SHANGHAI JUNSHI BIOSCIENCES
Shanghai Junshi Biosciences is a biopharmaceutical company.
SHANGHAI JUNSHI BIOSCIENCES
Industry:
Biopharma Biotechnology
Founded:
2012-01-01
Status:
Active
Contact:
86 21 5079 6193
Total Funding:
0
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Content Delivery Network Domain Not Resolving Mobile Non Scaleable Content Euro ASP.NET IIS
Similar Organizations
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
Shanghai Zhangjiang Yaogu Information Technology Service
Shanghai Zhangjiang Yaogu Information Technology Service is a pharmaceutical company.
Current Employees Featured
Founder
Stock Details
Investors List
Loyal Valley Capital
Loyal Valley Capital investment in Venture Round - Shanghai Junshi Biosciences
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2021-07-14 | GRIT Biotechnology | Shanghai Junshi Biosciences investment in Series A - GRIT Biotechnology | N/A |
| 2021-02-09 | Zhishan Weixin Biotechnology | Shanghai Junshi Biosciences investment in Series A - Zhishan Weixin Biotechnology | N/A |
| 2021-02-02 | Coherus Biosciences | Shanghai Junshi Biosciences investment in Post-IPO Equity - Coherus Biosciences | 50 M USD |
| 2020-12-01 | IMPACT Therapeutics | Shanghai Junshi Biosciences investment in Series C - IMPACT Therapeutics | 50 M USD |
More informations about "Shanghai Junshi Biosciences"
Investors | Shanghai Junshi biosciences Co., Ltd
Oct 12, 2024 With a mission of “providing patients with world-class, trustworthy, affordable, and innovative drugs,” Junshi Biosciences is “ In China, For Global.” At present, the company boasts approximately 3,000 employees in the United …See details»
Home - Junshi
Nov 24, 2022 Junshi Biosciences Announces Submission of a Marketing Authorization Application for Toripalimab to the UK Medicines and Healthcare Products Regulatory Agency …See details»
Shanghai Junshi Biosciences - Crunchbase
Shanghai Junshi Biosciences may be growing as evidenced by the FDA approval of Toripalimab for advanced nasopharyngeal cancer, which marks a significant milestone in the company's …See details»
Shanghai Junshi Biosciences Co., Ltd. - Drug pipelines, Patents ...
Explore Shanghai Junshi Biosciences Co., Ltd. with its drug pipeline, therapeutic area, technology platform, 236 clinical trials, 119 news, and 52 literature, Disease Domain:Neoplasms, Immune …See details»
Investors - 君实生物
Tel: （86）21-2024 8288 Fax: （86）21-50796192 Address:13/F, Building 2, No. 36 and 58, Haiqu Road, Pudong New Area, ShanghaiSee details»
R&D Pipeline - 君实生物
Focusing on innovation and patient accessibility, we have established a diversified and complementary R&D pipeline. Most products are independently developed through our own platform, and we have a number of potential novel …See details»
Domestically-developed cancer drug approved in US - 上海市政府
Nov 20, 2023 Shanghai Junshi Biosciences Co., Ltd. announced the approval of its LOQTORZI (toripalimab-tpzi) for the treatment of recurrent or metastatic Nasopharyngeal Carcinoma …See details»
Junshi Biosciences announces approval of the …
Jan 4, 2024 A logo of Shanghai Junshi Biosciences Co Ltd is seen at a pharmaceutical exhibition held in Shanghai, on June 20, 2023. [Photo/VCG] ... According to the World Health Organization, in 2020, the ...See details»
Shanghai Junshi Biosciences - Investments, Portfolio & Company …
Shanghai Junshi Biosciences has made 8 investments. Their most recent investment was on Nov 20, 2023 , when Ruotuo Bio raised How many investments has this organization made over time?See details»
Presentation Materials | Shanghai Junshi biosciences …
40th Annual J.P. Morgan Healthcare Conference - Junshi Biosciences' Presentation 2021 Q3 Results Presentation 2021 Interim Results PresentationSee details»
Junshi Biosciences announces approval of the supplemental new …
Nov 4, 2024 A logo of Shanghai Junshi Biosciences Co Ltd is seen at a pharmaceutical exhibition held in Shanghai, on June 20, 2023. ... According to the World Health Organization, …See details»
Shanghai Junshi Biosciences Co., Ltd.
Shanghai Junshi Biosciences Co., Ltd. Interim Results and Investor Presentation August, 2021. 2 Disclaimer The information, statements and opinions contained in this Presentation and …See details»
Shanghai Junshi Biosciences Relocates Key Offices - Nasdaq
Nov 29, 2024 Shanghai Junshi Biosciences Co., Ltd. Class H (HK:1877) has released an update.Don't Miss our Black Friday Offers:Unlock your investing potential with TipRanks …See details»
Junshi Biosciences Announces Approval of the Supplemental New …
SHANGHAI, China, January 2, 2024 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven …See details»
Junshi Biosciences: Announcement on the signing of the license …
Nov 20, 2024 Shanghai Junshi Biomedical Technology Co., Ltd Announcement on the signing of the license agreement The board of directors and all directors of the company guarantee that …See details»
Shanghai Junshi Biosciences Reduces Major Shareholders’ Stakes
Nov 12, 2024 Shanghai Junshi Biosciences Co., Ltd. has completed a plan reducing the shareholding of major shareholders who held more than 5% of the company’s shares. Before …See details»
01877 Stock Price Quote | Morningstar
5 days ago Shanghai Junshi Biosciences Co Ltd is a China-based biotechnology companyy with all-round capabilities in innovative drug discovery and development, clinical research on a …See details»
Careers - 君实生物
Company Introduction Founded in December 2012, Junshi Biosciences is an innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization …See details»
Shanghai Junshi Biosciences’ TUOYI Gains Key Insurance Inclusion
Shanghai Junshi Biosciences Co., Ltd. announced that its product, Toripalimab Injection (TUOYI), has been included in the National Drug List for Basic Medical Insurance with four new …See details»